Amphastar Pharmaceuticals Reports Q3 2026 Financial Results

Amphastar Pharmaceuticals reported third-quarter 2026 revenue of $207.6 million, exceeding the FactSet consensus estimate of $197.5 million. Adjusted earnings per share were $1.14, above analysts’ estimate of $0.86. The results cover the quarter ended September 30, 2026.